 | | Vol. 23.20 – 13 June, 2022 |
| |
|
|
| In this Phase III trial, adults with symptomatic myeloma received one cycle of lenalidomide, bortezomib, and dexamethasone.
[New England Journal of Medicine] |
|
 |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists designed chimeric receptors that have an orthogonal IL-2 receptor extracellular domain fused with the intracellular domain of receptors for common γ-chain cytokines IL-4, IL-7, IL-9 and IL-21 such that the orthogonal IL-2 cytokine elicited the corresponding γc cytokine signal.
[Nature] |
|
|
|
| Investigators transplanted cells from the embryonic mouse cerebral cortex into traumatic brain injury-injured, inflamed-only, or intact cortex of adult mice.
[Science Advances] |
|
|
|
| Through a comprehensive analysis of gene expression during the differentiation of mesenchymal stem cell into osteoblasts, the authors showed that the forkhead transcription factor Foxf2 was a crucial regulator of this process.
[Experimental & Molecular Medicine] |
|
|
|
| Researchers assessed the in vivo generation of CD19-CAR T cells in huSGM3 mice upon single intravenous injection of the T cell specific lentiviral vectors (LVs) CD4-LV and CD8-LV.
[Molecular Therapy-Methods & Clinical Development] |
|
|
|
| Scientists reported the generation of two novel hinge domains derived from the low-affinity p75 chain of the human nerve growth factor receptor (NGFR), termed N3 and N4, which, when incorporated into the CAR backbone, allowed detection as well as high-grade enrichment of CAR T-cells with GMP-compatible immunomagnetic reagents.
[Molecular Therapy-Oncolytics] |
|
|
|
| The authors designed a DAP10 chimeric receptor that utilized native NKG2D on T cells to target NKG2D ligand-expressing cancer cells.
[Molecular Therapy-Oncolytics] |
|
|
|
| Researchers demonstrated that HEK293, ARPE19, and patient induced pluripotent stem cell-derived RPE cells transduced with AAV2 vectors encoding codon optimization of CYP4V2 resulted in elevated protein expression levels of CYP4V2 compared to those transduced with AAV2 vectors encoding wild type.
[Scientific Reports] |
|
|
|
| Swabs from different skin areas were collected from 28 transplanted patients in this study. STR profiles were created and, as far as possible, used to determine the proportion of recipient to donor alleles.
[International Journal of Legal Medicine] |
|
|
|
|
| Investigators summarize the advantages, limitations, and future directions of cell replacement therapy, discussed the safety and ethical concerns of this novel therapeutic approach and the possibility of translation to clinical practice.
[Ageing Research Reviews] |
|
|
|
|
| Umoja Biopharma, Inc. and TreeFrog Therapeutics announced that they have entered into a collaboration to evaluate Umoja’s induced pluripotent stem cells platform within TreeFrog’s C-Stem™ technology for scalable expansion and immune cell differentiation in bioreactors.
[Umoja Biopharma, Inc.] |
|
|
|
|
| September 19 – 20 2022
Vejle, Denmark |
|
|
|
|
|
| | New York Blood Center – New York, New York, United States |
|
|
|
| | University of California, San Francisco – San Francisco, California, United States |
|
|
|
| | University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
| | Stem Cell Network – Ottawa, Ontario, Canada |
|
|
|
| | China Medical University – Shenyang, China |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
